Guru Ownership Trend
Guru Analysis for Nektar Therapeutics (NKTR)
Nektar Therapeutics (NKTR), a key player in the Healthcare sector, continues to attract institutional attention.
As of Q4 2025, a total of 3 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $51.67 M.
Top institutional holders include Steven Cohen and Renaissance Technologies (RenTech).
Institutional sentiment is currently Bullish. This is evidenced by a $231,974.85 net inflow during the quarter.
Recent activity highlights Steven Cohen who increased their stake by 250.5%. Conversely, Jefferies Group reduced exposure by 63.1%.
Key Holders
Top 5 by Value
Top 5 by Conviction
Recent Activity Breakdown (Q4 2025)
Guru Consensus (Q4 2025)
FAQs for Nektar Therapeutics (NKTR)
Major holders include Steven Cohen ($18.32 M), Renaissance Technologies (RenTech) ($7.31 M), Jefferies Group ($4.73 M). According to the latest reported data, 3 tracked investment managers collectively hold approximately 718,200 shares.
According to the latest 13F reporting period, sentiment appears Bullish (Net Buying). There was a net inflow of $231,974.85, with 1 managers increasing positions and 3 managers reducing holdings.
During the most recent reporting period, 2 managers trimmed their positions, while 1 fully exited NKTR. The total reported sell value was $12.86 M.
Yes, 0 managers opened new positions in NKTR, and 1 increased their existing holdings. The total reported buy value was $13.1 M.